Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Total Current Liabilities (2019 - 2025)

Biodesix (BDSX) has disclosed Total Current Liabilities for 7 consecutive years, with $17.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 21.79% year-over-year to $17.4 million, compared with a TTM value of $17.4 million through Dec 2025, up 21.79%, and an annual FY2025 reading of $17.4 million, up 21.79% over the prior year.
  • Total Current Liabilities was $17.4 million for Q4 2025 at Biodesix, down from $18.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $37.4 million in Q3 2022 and bottomed at $13.0 million in Q3 2024.
  • Average Total Current Liabilities over 5 years is $23.4 million, with a median of $22.4 million recorded in 2021.
  • The sharpest move saw Total Current Liabilities soared 84.89% in 2022, then tumbled 60.3% in 2024.
  • Year by year, Total Current Liabilities stood at $29.0 million in 2021, then dropped by 21.14% to $22.8 million in 2022, then surged by 46.31% to $33.4 million in 2023, then crashed by 57.16% to $14.3 million in 2024, then rose by 21.79% to $17.4 million in 2025.
  • Business Quant data shows Total Current Liabilities for BDSX at $17.4 million in Q4 2025, $18.2 million in Q3 2025, and $15.2 million in Q2 2025.